FOLFOX4方案治疗晚期胃癌的近期疗效分析  

Analysis of short-term effects of FOLFOX4 in the treatment of advanced gastric carcinoma

作　　者：徐鹏[1] 温红[1] 王睿[1] 

机构地区：[1]青岛市肿瘤医院外一科,青岛266042

出　　处：《肿瘤》2007年第8期660-662,共3页Tumor

摘　　要：目的:评价FOLFOX4方案治疗晚期胃癌的近期疗效及安全性。方法:32例晚期胃癌患者均有可评价的病灶,行FOLFOX4方案化疗:奥沙利铂(OXA)85 mg/m2静脉滴注2 h,第1天;醛氢叶酸(LV)200 mg/m2静脉滴注2 h,第1、2天;氟脲嘧啶(5-FU)400 mg/m2静脉推注后,以600 mg/m2持续静脉滴注22 h,第1、2天;2周重复1次,每2次为1个周期,所有患者至少接受4个周期的治疗。结果:完全缓解1例,部分缓解14例,总有效率46.9%(15/32),中位至疾病进展时间5.6个月。主要不良反应为轻度的外周神经系统感觉障碍、恶心呕吐及白细胞计数降低,无治疗相关死亡。结论:FOLFOX4方案对晚期胃癌疗效确切,毒副反应轻,可以作为晚期胃癌患者化疗方案选择。Objective：To evaluate the short-term efficacy and the safety of FOLFOX4 regimen for patients with advanced gastric carcinoma （AGC）. Methods：All of the 32 AGC patients Were assessable for the safety analysis and for response. Oxaliplatin （85 mg/ m2 ） was infused over 2 h on day 1. The leucovorin （ LV, 200 mg/m2 ） was infused for 2 h followed by bolus （400 mg,/m2 ） and a 22 h infusion （600 mg/m2 ） of 5-FU on day 1 and day 2. The treatment was repeated every 2 weeks and twice treatment as one cycle. All the patients received at least 4 cycles of treatment. Results：Of the 32 patients, 1 patient had complete response and 14 patients had partial responses （overall response rate 46.9%, 15/32 ）. The median time to progression （TTP） was 5.6 months. The major adverse effects were mild peripheral neuropathy, nausea/vomiting and neutropenia. No treatment-related death occurred. Conclusion：FOLFOX4 regimen has good efficacy on AGC with relatively light toxicity. It could be selectedas chemotherapy regimen for AGC patients.

关 键 词：胃肿瘤 药物疗法 联合 药物副反应报告系统 

分 类 号：R735.2[医药卫生—肿瘤]